FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma

FYB2 (also known as C1orf168 or ARAP) is an adaptor protein involved in T-cell receptor (TCR)-mediated T-cell activation and adhesion. However, the correlation of FYB2 with prognosis and cancer needs further investigation. In this study, we analyzed the expression levels of FYB2 in hepatocellular ca...

Full description

Saved in:
Bibliographic Details
Published inLivers Vol. 2; no. 4; pp. 361 - 371
Main Authors Qu, Yifan, Shen, Xiaozhong, Yuan, Xinpei, Lu, Bing
Format Journal Article
LanguageEnglish
Published Kansas City MDPI AG 01.12.2022
Subjects
Annotations
Biomarkers
Datasets
FYB2
Gene expression
Genomes
Liver cancer
liver hepatocellular carcinoma
Medical prognosis
Mortality
prognostic biomarker
Regression analysis
Survival analysis
Tumors
Online AccessGet full text

Cover

More Information
Summary:FYB2 (also known as C1orf168 or ARAP) is an adaptor protein involved in T-cell receptor (TCR)-mediated T-cell activation and adhesion. However, the correlation of FYB2 with prognosis and cancer needs further investigation. In this study, we analyzed the expression levels of FYB2 in hepatocellular carcinoma (LIHC) tumor tissues and correlated it with the pathological stages, survival outcomes, and tumor grades. We found that the expression of FYB2 was significantly downregulated in LIHC. Low FYB2 level leading to weak survival outcomes is linked with advanced tumor grades and elevated pathological stages. Cox regression analysis showed that FYB2 and AJCC-M stages can be used as independent prognostic factors for LIHC. GSEA analysis revealed that FYB2 would be notably correlated with the cellular metabolism-related pathways and particularly involved in the regulation of cancer-related pathways. Single-cell transcriptome analysis revealed that FYB2-positive cells were mainly distributed in hepatocytes, and compared with other cells, the upregulated genes of these cells were mainly enriched in metabolism-related functions. The results of the spatial transcriptome revealed that the expression of FYB2 in the adjacent area was higher than in the tumor area. These results showed that FYB2 is likely to be a new prognostic biomarker in LIHC and would help provide individual treatment decisions for LIHC patients.
ISSN:2673-4389
2673-4389
DOI:10.3390/livers2040027